| Net income | 265.27M |
| Depreciation | 165.67M |
| Amortization of debt issuance costs | |
| Amortization of deferred items | |
| Provision for doubtful accounts | |
| Provision for inventory obsolescence | |
| Deferred income tax expense (benefit) | 1.63M |
| Share-based compensation expense | 11.86M |
| Other, net | |
| Decrease in accounts receivable | 176.61M |
| Decrease in insurance receivable | |
| Decrease (increase) in income tax receivable | 2.61M |
| Increase in inventory | 12.39M |
| Decrease in prepaid expenses | 7.5M |
| Increase in deferred costs and other assets | |
| Increase in accounts payable | -36.23M |
| Increase in accrued liabilities | -16.3M |
| Decrease in income tax payable | -5.61M |
| Increase (decrease) in deferred credits and other liabilities | |
| Net cash provided by operating activities | 625.01M |
| Capital expenditures | -223.73M |
| Proceeds from insurance | |
| Proceeds from sale of assets | 20.79M |
| Net cash used by investing activities | -202.94M |
| Principal payments on debt | |
| Proceeds from debt | |
| Proceeds from exercise of stock options | |
| Debt issuance costs paid | -451K |
| Net cash provided and used by financing activities | -390.63M |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 31.44M |
| CASH AND CASH EQUIVALENTS, at beginning of period | 113.98M |
| CASH AND CASH EQUIVALENTS, at end of period | 145.43M |
| Increase (decrease) in accounts payable and accrued liabilities related to capital expenditures | |